|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-5-19
|
|
pubmed:abstractText |
In 29 antiretroviral-naive HIV-2-infected patients starting lopinavir/ritonavir-containing regimen, the median CD4 cell count change from baseline (142 cells/microl) was +71 cells/microl at week 24 and +132 cells/microl at week 96. Seventeen (59%) patients had a CD4 cell count increase of at least 50 cells/microl and undetectable HIV-2 RNA at week 24 and were considered as responders to treatment. This sustained elevation of CD4 cell count in the first 2 years of combination antiretroviral therapy shows the potential for lopinavir/ritonavir regimens as first-line therapy in HIV-2 infection.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1473-5571
|
|
pubmed:author |
pubmed-author:ANRS CO5 HIV-2 Cohort Study Group,
pubmed-author:AutranBrigitteB,
pubmed-author:BénardAntoineA,
pubmed-author:Brun-VézinetFrançoiseF,
pubmed-author:CampaPaulineP,
pubmed-author:ChêneGenevièveG,
pubmed-author:DamondFlorenceF,
pubmed-author:DescampsDianeD,
pubmed-author:Lascoux-CombesCarolineC,
pubmed-author:MatheronSophieS,
pubmed-author:PeytavinGillesG,
pubmed-author:SimonFrançoisF,
pubmed-author:TaiebAudreyA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1171-3
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19349850-Adult,
pubmed-meshheading:19349850-CD4 Lymphocyte Count,
pubmed-meshheading:19349850-Drug Therapy, Combination,
pubmed-meshheading:19349850-Female,
pubmed-meshheading:19349850-HIV Infections,
pubmed-meshheading:19349850-HIV Protease Inhibitors,
pubmed-meshheading:19349850-HIV-2,
pubmed-meshheading:19349850-Humans,
pubmed-meshheading:19349850-Lopinavir,
pubmed-meshheading:19349850-Male,
pubmed-meshheading:19349850-Middle Aged,
pubmed-meshheading:19349850-Pyrimidinones,
pubmed-meshheading:19349850-Ritonavir,
pubmed-meshheading:19349850-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
|
|
pubmed:affiliation |
INSERM U897, CIC-EC 7, Université Victor Segalen Bordeaux 2, France. antoine.benard@isped.u-bordeaux2.fr
|
|
pubmed:publicationType |
Letter,
Research Support, Non-U.S. Gov't
|
